⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 5, 2021BMJ

Covid-19: The E484K mutation and the risks it poses

View at Publisher

Ask AI

Bookmark

Share

Abstract

The mutation E484K, first identified in the South African SARS-CoV-2 variant, has now been identified in the UK fast-spreading variant, prompting fears the virus is evolving further and could become resistant to vaccines. Jacqui Wise looks at what we know so far

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jacqui Wise (2021) studied this question.

synapsesocial.com/papers/6a5e124f646f15684ebc4d26 https://doi.org/10.1136/bmj.n359

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variantHuman Clinical Trial · 2021 · 235 citations
2Covid-19: Surge testing for the South Africa variant begins in EnglandOriginal Research · 2021 · 4 citations
3Conflict and climate are compounding challenges for women’s and children’s healthBMJ · Wed,
4Acetic acid chromoendoscopy for detection of neoplastic Barrett’s oesophagus: stepped wedge cluster randomised controlled trial (ACID-trial)BMJ · Wed,
5Green transition provides a crucial opportunity to finance universal health coverageBMJ · Wed,

More from BMJ

In South Asia the most vulnerable people are paying for a climate crisis created by high income countriesWed,
Effectiveness of a structured template to improve completeness of reporting randomised trial protocols: randomised controlled trialTue,
Wildfires are putting firefighters at risk of cancer—scientists are working out how to helpTue,
Private providers are profiting from the expansion of ADHD and autism diagnosisTue,
How the brain changes during menopause—and why we still don’t know what it meansFri,